AstraZeneca Expands Fasenra’s Label to Younger Children with Severe Asthma

[cafead]

via The FDA on Thursday greenlit the label expansion of AstraZeneca’s subcutaneous IL-5 receptor blocker Fasnera (benralizumab), which can now be used as an add-on maintenance treatment for severe eosinophilic asthma in children six to 11 years of age.

article source